OMNIA WELLNESS INC.

$ Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222033843 Filed on November 28, 2022

Income Statement

Concept	2022 Q3	2021 Q3

Balance Sheet

Concept	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$0.00	$67.33K
YoY Change	-100.0%
Cash & Equivalents		$67.33K
Short-Term Investments
Other Short-Term Assets		$40.00K
YoY Change
Inventory	$24.00K
Prepaid Expenses
Receivables	$54.25K
Other Receivables	$89.51K
Total Short-Term Assets	$167.8K	$381.0K
YoY Change	-55.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$501.8K	$417.6K
YoY Change	20.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.970M	$1.919M
YoY Change	2.67%
TOTAL ASSETS
Total Short-Term Assets	$167.8K	$381.0K
Total Long-Term Assets	$1.970M	$1.919M
Total Assets	$2.137M	$2.300M
YoY Change	-7.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$981.3K	$112.5K
YoY Change	772.42%
Accrued Expenses	$893.4K	$441.3K
YoY Change	102.45%
Deferred Revenue
YoY Change
Short-Term Debt	$1.398M	$5.711M
YoY Change	-75.52%
Long-Term Debt Due	$4.320M
YoY Change
Total Short-Term Liabilities	$7.876M	$6.311M
YoY Change	24.78%
LONG-TERM LIABILITIES
Long-Term Debt	$378.5K	$148.6K
YoY Change	154.65%
Other Long-Term Liabilities	$197.2K
YoY Change
Total Long-Term Liabilities	$575.7K	$148.6K
YoY Change	287.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.876M	$6.311M
Total Long-Term Liabilities	$575.7K	$148.6K
Total Liabilities	$8.451M	$6.460M
YoY Change	30.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.23M
YoY Change
Common Stock	$231.5K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.314M	-$4.161M
YoY Change
Total Liabilities & Shareholders Equity	$2.137M	$2.300M
YoY Change	-7.05%

Cashflow Statement

Concept	2022 Q3	2021 Q3

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	OMWS	Secured Debts SecuredDebts		usd
CY2022Q3	us-gaap	Secured Debt SecuredDebt		usd
CY2022Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
	OMWS	Bad Debt Expense BadDebtExpense		usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	OMWS	Increase Decrease In Deposit Liability IncreaseDecreaseInDepositLiability		usd
CY2022Q3	us-gaap	Deposit Liability Current DepositLiabilityCurrent		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	OMWS	Payment For Subscriptions Receivable PaymentForSubscriptionsReceivable		usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
	OMWS	Payment For Subscriptions Receivable PaymentForSubscriptionsReceivable		usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
	OMWS	Product Warranty Expenses ProductWarrantyExpenses		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001676852
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		usd
	OMWS	Product Warranty Expenses ProductWarrantyExpenses		usd
CY2022Q3	OMWS	Product Warranty Expenses ProductWarrantyExpenses		usd
CY2021Q3	OMWS	Product Warranty Expenses ProductWarrantyExpenses		usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	OMWS	Other Selling General And Administrative Expense Related Party OtherSellingGeneralAndAdministrativeExpenseRelatedParty		usd
	OMWS	Other Selling General And Administrative Expense Related Party OtherSellingGeneralAndAdministrativeExpenseRelatedParty		usd
CY2022Q3	OMWS	Other Selling General And Administrative Expense Related Party OtherSellingGeneralAndAdministrativeExpenseRelatedParty		usd
CY2021Q3	OMWS	Other Selling General And Administrative Expense Related Party OtherSellingGeneralAndAdministrativeExpenseRelatedParty		usd
	OMWS	Consulting Expense ConsultingExpense		usd
CY2021Q3	OMWS	Consulting Expense ConsultingExpense		usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating		usd
CY2021Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating		usd
	OMWS	Royalty Expense Income RoyaltyExpenseIncome		usd
CY2021Q3	OMWS	Royalty Expense Income RoyaltyExpenseIncome		usd
	OMWS	License Royalties LicenseRoyalties		usd
	OMWS	License Royalties LicenseRoyalties		usd
CY2022Q3	OMWS	License Royalties LicenseRoyalties		usd
CY2021Q3	OMWS	License Royalties LicenseRoyalties		usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	OMWS	Gain On Ppp Loan Forgiven GainOnPppLoanForgiven		usd
CY2022Q3	OMWS	Gain On Ppp Loan Forgiven GainOnPppLoanForgiven		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q2	OMWS	Reclass Par Value Of Shares And Shares Outstanding ReclassParValueOfSharesAndSharesOutstanding		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	OMWS	Amortization Of Warrants AmortizationOfWarrants		usd
	OMWS	Amortization Of Warrants AmortizationOfWarrants		usd
	OMWS	Discount On Notes DiscountOnNotes		usd
	OMWS	Discount On Notes DiscountOnNotes		usd
	OMWS	Royalty On Sales RoyaltyOnSales		usd
	OMWS	Finance Costs Related To Note Payable FinanceCostsRelatedToNotePayable		usd
	OMWS	Finance Costs Related To Note Payable FinanceCostsRelatedToNotePayable		usd
	OMWS	Finance Costs Paid In Stock FinanceCostsPaidInStock		usd
	OMWS	Finance Costs Paid In Stock FinanceCostsPaidInStock		usd
	OMWS	Gain Loss On Ppp Loan Forgiven GainLossOnPppLoanForgiven		usd
	OMWS	Rent Payments On Lease Liability RentPaymentsOnLeaseLiability		usd
	OMWS	Bad Debt Expense BadDebtExpense		usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability		usd
CY2021Q3	us-gaap	Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation		usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-211986
	dei	Entity Registrant Name EntityRegistrantName	OMNIA WELLNESS INC
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1291924
	dei	Entity Address Address Line1 EntityAddressAddressLine1	999 18th Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 3000
	dei	Entity Address City Or Town EntityAddressCityOrTown	Denver
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80202
	dei	City Area Code CityAreaCode	(888)
	dei	Local Phone Number LocalPhoneNumber	320-5711
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	231505146	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1894	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	54251	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	118349	usd
CY2022Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	89505	usd
CY2022Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	91380	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	24000	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	24000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	167756	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	235623	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	501778	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	515113	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1350850	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1450900	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117098	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	160197	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	1969726	usd
CY2022Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	2126210	usd
CY2022Q3	us-gaap	Assets Assets	2137482	usd
CY2022Q1	us-gaap	Assets Assets	2361833	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	981301	usd
CY2022Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	562213	usd
CY2022Q1	us-gaap	Deposit Liability Current DepositLiabilityCurrent	8002	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	893443	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	615261	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	101465	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99464	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	25667	usd
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	25667	usd
CY2022Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	155289	usd
CY2022Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	143817	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1852735	usd
CY2022Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1102735	usd
CY2022Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1792566	usd
CY2022Q1	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1765219	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	29970	usd
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	29970	usd
CY2022Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1368193	usd
CY2022Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1229443	usd
CY2022Q3	OMWS	Secured Debts SecuredDebts	675000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7875629	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5581791	usd
CY2022Q3	OMWS	Due To Related Party Noncurrent DueToRelatedPartyNoncurrent	163239	usd
CY2022Q1	OMWS	Due To Related Party Noncurrent DueToRelatedPartyNoncurrent	143239	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33997	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	80099	usd
CY2022Q1	us-gaap	Secured Debt SecuredDebt	675000	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	141920	usd
CY2022Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	891920	usd
CY2022Q3	OMWS	Nonconvertible Notes Non Related NonconvertibleNotesNonRelated	166571	usd
CY2022Q1	OMWS	Nonconvertible Notes Non Related NonconvertibleNotesNonRelated	189918	usd
CY2022Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	70000	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	575727	usd
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1980176	usd
CY2022Q3	us-gaap	Liabilities Liabilities	8451356	usd
CY2022Q1	us-gaap	Liabilities Liabilities	7561967	usd
CY2022Q3	OMWS	Stock Payable StockPayable	230367	usd
CY2022Q1	OMWS	Stock Payable StockPayable	642867	usd
CY2022Q3	OMWS	Stock Reserve StockReserve	412500	usd
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	150000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	150000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	231505146	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	231505146	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	232222818	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	232222818	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	231505	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	232223	usd
CY2022Q3	OMWS	Common Stock Subscribed Par Or Stated Value Per Share CommonStockSubscribedParOrStatedValuePerShare	0.001
CY2022Q1	OMWS	Common Stock Subscribed Par Or Stated Value Per Share CommonStockSubscribedParOrStatedValuePerShare	0.001
CY2022Q3	OMWS	Common Stock Subscribed Shares Outstanding CommonStockSubscribedSharesOutstanding	2500000	shares
CY2022Q1	OMWS	Common Stock Subscribed Shares Outstanding CommonStockSubscribedSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	2500	usd
CY2022Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	2500	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5445438	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5344318	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12226184	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11012042	usd
CY2022Q3	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	410000	usd
CY2022Q1	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	410000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-6313874	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-5200134	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2137482	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2361833	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	162092	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	94931	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28446	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57809	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	98500	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15010	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	77534	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8477	usd
	us-gaap	Cost Of Revenue CostOfRevenue	98500	usd
	us-gaap	Cost Of Revenue CostOfRevenue	15010	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	77534	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	8477	usd
	us-gaap	Gross Profit GrossProfit	63592	usd
	us-gaap	Gross Profit GrossProfit	79921	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	-49088	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	49332	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	190783	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	143036	usd
	us-gaap	Professional Fees ProfessionalFees	356002	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1536678	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	95448	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	72557	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6000	usd
CY2022Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6000	usd
	us-gaap	Professional Fees ProfessionalFees	85559	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	83780	usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	255048	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	219501	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	84104	usd
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	88230	usd
CY2021Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	58937	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20779	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	30920	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2220	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	30544	usd
	OMWS	Consulting Expense ConsultingExpense	44180	usd
CY2022Q3	OMWS	Consulting Expense ConsultingExpense	27239	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	91000	usd
CY2022Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	45000	usd
	OMWS	Royalty Expense Income RoyaltyExpenseIncome	-11472	usd
CY2022Q3	OMWS	Royalty Expense Income RoyaltyExpenseIncome	3805	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	150096	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	68412	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	64776	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9184	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48200	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	732000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	397500	usd
	us-gaap	Operating Expenses OperatingExpenses	867570	usd
	us-gaap	Operating Expenses OperatingExpenses	1414474	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	408889	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	823770	usd
	OMWS	Gain On Ppp Loan Forgiven GainOnPppLoanForgiven	443873	usd
CY2021Q3	OMWS	Gain On Ppp Loan Forgiven GainOnPppLoanForgiven	146959	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	410164	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1045638	usd
CY2022Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	176640	usd
CY2021Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	918807	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-410164	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-601765	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-176640	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-771848	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1214142	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1936318	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-634617	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1546286	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	231507112	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	224213846	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	231509068	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	224213846	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-3408641	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	430123	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-390032	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-3368550	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	754291	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1546286	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-4160545	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-5200134	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	77561	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-579526	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-5702099	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-5702099	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	22841	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-634617	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-634617	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-6313874	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-6313874	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1214142	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1936318	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	147685	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	143576	usd
	OMWS	Convertibles Notes Convertible Beneficial Conversion Feature ConvertiblesNotesConvertibleBeneficialConversionFeature	100402	usd
	OMWS	Convertibles Notes Convertible Beneficial Conversion Feature ConvertiblesNotesConvertibleBeneficialConversionFeature	771576	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	43099	usd
	OMWS	Royalty On Sales RoyaltyOnSales	11472	usd
	OMWS	Gain Loss On Ppp Loan Forgiven GainLossOnPppLoanForgiven	440266	usd
	OMWS	Rent Payments On Lease Liability RentPaymentsOnLeaseLiability	44101	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-64098	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	72418	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-1875	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	24000	usd
	OMWS	Increase Decrease In Deposit Liability IncreaseDecreaseInDepositLiability	8002	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	449088	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7771	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	278182	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	13401	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-170344	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	212750	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34300	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	146750	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34300	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-146750	usd
	OMWS	Proceeds From Advances ProceedsFromAdvances	20000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1309154	usd
	OMWS	Payments On Advances PaymentsOnAdvances	30000	usd
	OMWS	Payments For Decrease In Stock Subscription Payable PaymentsForDecreaseInStockSubscriptionPayable	412500	usd
	OMWS	Proceeds From Increase In Stock Reserve ProceedsFromIncreaseInStockReserve	412500	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	718	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-718	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	412839	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	202750	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1721993	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1894	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	38565	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1894	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28761	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	67326	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zgmZHVgYrOn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Note 1 <span id="xdx_822_zUlEHaVgJhnc">Nature of Operations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omnia Wellness Inc. (the “Company”) was incorporated as a Nevada corporation on <span id="xdx_902_edei--EntityIncorporationDateOfIncorporation_c20220401__20220930_zhLlIN5ef2Jh" title="Entity incorporation, date of incorporation">March 2, 2016</span>, by the filing of articles of incorporation with the Secretary of State of the State of <span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20220401__20220930_zTrCrCWwX1W7" title="Entity incorporation, state or country code">Nevada</span> under the name Glolex, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20220401__20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MaksimCharniakMember_zdFDn6ULBWl4" title="Equity method investment description">On June 25, 2019, Maksim Charniak, the Company’s then sole executive officer and director and the owner of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_c20190624__20190625__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MrAmerSamadMember_zq3M6MNDkIBl" title="Stock split shares">3,000,000</span> shares (pre- stock split) of the Company’s common stock, sold all his shares of common stock of the Company to Amer Samad, resulting in a change of control of the Company. As part of that transaction, Mr. Charniak resigned from all of his officer and director positions, and Mr. Samad was appointed as the Chief Executive Officer, President, Chief Financial Officer and Secretary of the Company, and was appointed to the Board of Directors of the Company. Mr. Samad also purchased 1,167,937 shares (pre-stock split) of the Company’s common stock in a series of private transactions, resulting in Mr. Samad owning 4,167,937 shares (pre-stock split) of the Company’s common stock, or approximately <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190625__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MrAmerSamadMember_zYq2bmCjikki" title="Ownership percentage">95.6</span>% of the issued and outstanding common stock of the Company.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 5, 2020, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to, among other things, (i) increase the Company’s authorized shares of common stock from <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20200304_zYNMxwXkLvRb" title="Common stock, shares authorized">75,000,000</span> to <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20200305_zkDRxXsvcll5" title="Common stock, shares authorized">100,000,000</span>, (ii) create and authorize <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20200305__srt--StatementScenarioAxis__custom--BlankCheckMember_zqBrB67ouOa5" title="Preferred stock authorized">10,000,000</span> shares of “blank check” preferred stock, and (iii) effect a <span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20200303__20200305_z1Ia8OqZYN1j" title="Forward stock split">12.6374:1</span> forward stock split of the common stock. In addition, on March 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to change the name of the Company from Glolex Inc. to Omnia Wellness Inc. On April 15, 2020, the stock of the Company began trading on the OTC Pink market under the symbol “OMWS”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 17, 2020, the Company entered into a Share Exchange and Reorganization Agreement (the “Exchange Agreement”) with Omnia Wellness Corporation (formerly known as Bed Therapies Inc.), a Texas corporation (“Omnia Corp.”), and the beneficial stockholders of Omnia Corp. to acquire <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zlyvUWGUHQ95" title="Ownership percentage">100</span>% of the issued and outstanding shares of capital stock of Omnia Corp. The transactions contemplated by the Exchange Agreement were consummated on January 5, 2021, and, pursuant to the terms of the Exchange Agreement, among other things, all outstanding shares of common stock of Omnia Corp., no par value, or the Omnia Corp. Shares, were exchanged for shares of the Company’s common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zoVvTfRZiGf1" title="Common stock, par value">0.001</span> per share, based on the exchange ratio of one share of the Company’s common stock for every one Omnia Corp. Share. The Company refers herein to the transactions contemplated by the Exchange Agreement, collectively, as the Acquisition. <span id="xdx_903_eus-gaap--StockholdersEquityNoteStockSplit_c20210404__20210406__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zFbNEAsBm4f8" title="Forward stock split description">Accordingly, the Company acquired 100% of Omnia Corp. in exchange for the issuance of 10,000,000 (not adjusted to reflect the Company’s 15:1 forward stock split on April 6, 2021) shares of the Company’s common stock and Omnia Corp. became the Company’s wholly owned subsidiary. As of the closing of the Acquisition (the “Closing”), Mr. Samad, resigned as an officer and director of the Company and agreed to cancel <span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_c20200416__20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember__srt--TitleOfIndividualAxis__custom--MrAmerSamadMember_zCvzOz7isHW8" title="Cancellation of stock split">52,656,888</span></span> (pre-stock split) shares of the Company’s common stock owned beneficially and of record by him as part of the conditions to Closing, which were cancelled immediately following the Closing. The Company also issued an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_c20210104__20210105__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zT66TGEC1Zpj" title="Stock issued during period shares stock splits">1,269,665</span> (pre-stock split) shares of common stock on January 5, 2021, as a result of the conversion in accordance with their terms of outstanding convertible promissory notes in the aggregate principal amount of approximately $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20200416__20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zDJVV05CQv7k" title="Debt conversion, converted instrument, amount">539,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of immediately prior to the closing of the Acquisition, the Company entered into an Assignment and Assumption Agreement with RZI Consulting LLC (the “Assignment Agreement”), pursuant to which RZI Consulting LLC assumed substantially all of the Company’s remaining assets and liabilities through the closing of the Acquisition. Accordingly, as of the closing of the Acquisition, the Company had no assets or liabilities (other than relating to general and administrative expenses).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the Acquisition, the Company, through its wholly owned subsidiary Omnia Corp., now develops and markets products for wellness and physical therapy markets, using patented dry-hydro therapy equipment that the Company plans to offer and sell in medical and fitness markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 6, 2021, <span id="xdx_909_eus-gaap--StockholdersEquityNoteStockSplit_c20210404__20210406__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--BedTherapiesIncMember__srt--TitleOfIndividualAxis__custom--MrAmerSamadMember_zaQdQpmmp74d" title="Stockholders equity description">the Company filed a Certificate of Change with the Secretary of State of the State of Nevada to (i) increase the Company’s authorized shares of common stock from <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MinimumMember_z8f6rd6SIv16" title="Common stock, shares authorized">100,000,000</span> to <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MaximumMember_ztkU7AsbxA4j" title="Common stock, shares authorized">1,500,000,000</span>, (ii) increase the Company’s authorized shares of “blank check” preferred stock from <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MinimumMember_zRzw20wuMsgb" title="Preferred stock authorized">10,000,000</span> to <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MaximumMember_z9PO49G1DZha" title="Preferred stock authorized">150,000,000</span>, and (iii) effect a 1:15 forward stock split of the common stock.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s principal executive office is located at 999 18<sup>th</sup> St., Suite 3000, Denver, CO 80202, and its telephone number is 303-325-3738. The Company’s website address is www.omniawellness.com.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020 the World Health Organization declared COVID-19 a pandemic. The Company is still assessing the impact COVID-19 may have on its business, but there can be no assurance that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally. The extent to which the COVID-19 pandemic and global efforts to contain its spread will impact the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2016-03-02
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	12.6374:1
	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de- recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.
CY2019Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100050	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zUAn5v8AX5of" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zXb6z61wEhEl">Accounting Estimates</span> </i></b>- The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: the allowance for doubtful accounts, determination of impairment on investments and determination of recoverability of deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zNKmbSKSHQbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zN4ZurRzMeA1">Risks and Uncertainties</span></i></b> - The Company’s operations may be subject to significant risk and uncertainties including financial, operational, regulatory, and other risks associated with a start-up company, including the potential risk of business failure. See Note 3 regarding going concern matters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	231505146	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	224227107	shares
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	54251	usd
CY2021Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	66950	usd
	us-gaap	Depreciation Depreciation	147684	usd
	us-gaap	Depreciation Depreciation	143036	usd
CY2019Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	350000	usd
CY2019Q2	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	1000	usd
CY2019Q4	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	200000	usd
CY2022Q3	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	0	usd
CY2021Q3	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	40000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation	241854	usd
CY2021Q3	us-gaap	Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation	169230	usd
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	650150	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	500075	usd
CY2020Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1450000	usd
CY2022Q3	OMWS	Royalty Liability RoyaltyLiability	32808	usd
CY2022Q3	OMWS	Monthly Sales Percent MonthlySalesPercent	0.05	pure
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	892004	usd
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	669304	usd
CY2022Q3	OMWS	Property Plant And Equipment And Intangible Assets Net PropertyPlantAndEquipmentAndIntangibleAssetsNet	1852628	usd
CY2021Q3	OMWS	Property Plant And Equipment And Intangible Assets Net PropertyPlantAndEquipmentAndIntangibleAssetsNet	1918527	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100050	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	135462	usd
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	Our assessment is based on (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period and (3) whether we have the right to direct the use of the asset. Leases are classified as either finance leases or operating leases.
CY2022Q3	us-gaap	Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation	147363	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117098	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	101465	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33997	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	135462	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	44101	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	8080	usd
CY2021	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	1.0	pure
CY2021Q2	OMWS	Gain On Ppp Loan Forgiven GainOnPppLoanForgiven	294066	usd
CY2021Q3	OMWS	Gain On Ppp Loan Forgiven GainOnPppLoanForgiven	146200	usd
CY2021Q4	OMWS	Gain On Ppp Loan Forgiven GainOnPppLoanForgiven	148625	usd
CY2022Q1	OMWS	Gain On Ppp Loan Forgiven GainOnPppLoanForgiven	593546	usd
CY2021Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	513827	usd
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	1014478	usd
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	771576	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022Q3	us-gaap	Area Of Land AreaOfLand	200	sqft

Files In Submission

Name	View Source	Status
0001493152-22-033843-index-headers.html	Edgar Link	pending
0001493152-22-033843-index.html	Edgar Link	pending
0001493152-22-033843.txt	Edgar Link	pending
0001493152-22-033843-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
omws-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
omws-20220930_cal.xml	Edgar Link	unprocessable
omws-20220930_pre.xml	Edgar Link	unprocessable
omws-20220930_def.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
omws-20220930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

OMNIA WELLNESS INC.

2022 Q3 Form 10-Q Financial Statement

#000149315222033843 Filed on November 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission